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Abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove 
and interacts with proteins of the DNA repair machinery. Phase I trials have established 
the standard regimen as 1500 µg/m² 24-hour continuous infusion repeated every 3 weeks. 
Several phase II trials have shown response in 5%–10% of unselected patients with soft 
tissue sarcoma failing prior chemotherapy and disease stabilisation in 30%–40%. Further-
more, prolonged disease control has been described in 15%–20% of patients. Toxicities 
are mainly haematological and hepatic with grade 3–4 neutropenia and thrombocytopenia 
observed in approximately 50% and 20% of patients respectively, and grade 3–4 elevation 
of liver enzymes observed in 35%–50% of patients treated with trabectedin. Current research 
focuses on the identiﬁ  cation of predictive factors for patients with soft tissue sarcoma treated 
with trabectedin.
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Introduction
Soft-tissue sarcomas (STS) are rare tumors of mesenchymal origin. Approximately 
30%–50% of patients will experience metastatic relapse despite optimal locoregional 
treatment. In the setting of advanced or metastatic disease, systemic chemotherapy is 
indicated, although local therapies, such as surgery and radiation therapy, may achieve 
long term survival in selected patient (Clark et al 2005).
Doxorubicin alone or combined with ifosfamide has been the backbone of systemic 
chemotherapy for metastatic or advanced STS for more than 20 years with objec-
tive response observed in 15%–35% of patients (Wilson et al 1986; Antman et al 
1993; Edmonson et al 1993). No standard treatment has yet emerged after failure of 
doxorubicin containing chemotherapy though some agents such as gemcitabine and 
gemcitabine-docetaxel combination have shown promising results (Patel et al 2001; 
Hensley et al 2002; Bay et al 2006). Trabectedin (ET743, YONDELIS®, PharmaMar, 
Madrid, Spain), a tetrahydroisoquinoline alkaloid, is a natural product derived from 
the marine tunicate Ecteinascidia turbinata. ET743 has shown potent antitumor activ-
ity in preclinical studies both in vitro and in vivo on several solid tumors, including 
ovarian and breast cancer, melanoma, and sarcoma. These preclinical data have been 
conﬁ  rmed in several phase II trials in breast and ovarian carcinoma, as well as STS. 
However, as with many other cytotoxic agents, the precise mechanism of trabectedin’s 
cytotoxicity remains unclear.
Mechanism of action
Trabectedin (ET743) binds to the minor groove of DNA and alkylates guanine at 
the N2 position, whereas most alkylating agents bind guanine at position N7 or O6 
in the major groove. Binding of trabectedin has been shown to be DNA-sequence Therapeutics and Clinical Risk Management 2008:4(1) 110
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speciﬁ  c, with GC rich triplets more frequently bound 
(David-Cordonnier et al 2005). Covalent binding of tra-
bectedin induces DNA bending towards the major groove 
and a widening of the DNA minor groove (Takebayashi, 
Pourquier et al 2001). Modiﬁ  cation of the DNA confor-
mation leads to inhibition of activated transcription while 
constitutive transcription seems unaffected (Friedman 
et al 2002).
Several reports have underlined the importance of 
nucleotide-excision repair (NER) in the cytotoxicity of 
ET743, and more precisely the cell-killing ability of this 
drug has been linked to the transcription-coupled NER 
(TC-NER) (Takebayashi, Pourquier et al 2001; David-Cor-
donnier et al 2005; Herrero et al 2006). The DNA bending 
induced by the binding of trabectedin to the minor groove 
is detected by the TC-NER machinery, which in the repair 
process makes single strand breaks (SSBs) on each side of 
the lesion (David-Cordonnier et al 2005). These breaks are 
then made irreversible by the DNA-protein crosslinking 
capacities of trabectedin (Takebayashi, Goldwasser et al 
2001). Recently Herrero et al (2006) suggested a slightly 
different model based on their observations made in the 
yeast model Schizosaccharomyces pompe. In this model, 
cells deﬁ  cient for Rad13 (the yeast equivalent to the human 
XPG, which is an endonuclease of the NER system), were 
resistant to trabectedin, while those with an inactive Rad51 
(a protein of the homologous recombination repair (HRR) 
pathway, involved in the repair of double stand breaks) 
were more sensitive to trabectedin than the wild-type 
cells. Based on these observations Herrero et al (2006) 
suggested the following sequence: trabectedin binds cova-
lently to the DNA minor groove and the resulting adduct 
is recognised by the NER machinery, then the recruited 
Rad13 (XPG) protein binds to DNA and interacts with the 
minor groove-bound drug by means of an arginine residue 
located in the COOH terminus, other proteins of the NER 
machinery trying to repair the damage are then hijacked, 
forming larger, more toxic complexes. Lastly, during the 
S phase, the aforementioned complexes give rise to double 
stand DNA breaks, explaining the sensitivity of cells deﬁ  -
cient for HRR pathway proteins (eg, Rad51) (Herrero et al 
2006). In a recently published study, Soares et al (2007) 
showed that human cell lines deﬁ  cient for the HRR proteins 
XRCC3, BRCA2, RAD51C and XRCC2 were 8 to 23 times 
more sensitive to treatment with trabectedin. Furthermore, 
their data shows that trabectedin-DNA adducts induce the 
formation of highly cytotoxic double strand breaks during 
the S-phase of the cell cycle (Soares et al 2007), thereby 
conﬁ  rming, in human cell lines, the scenario suggested by 
Herrero et al (2006).
Toxicity of trabectedin
Common side effects of trabectedin 
in clinical trials
Three phase I trials were conducted concomitantly in the 
United States, France and in Europe.
The American study, conducted by the teams of the 
Massachusetts General Hospital and the Dana-Farber Cancer 
Institute, tested the safety of trabectedin administered as a 
continuous infusion over 72 hours (Ryan et al 2001). In 
this trial enrolling 21 patients with various types of solid 
malignancies (including 6 sarcomas) the maximum toler-
ated dose (MDT) was 1200 µg/m² over 72 hours every 
3 weeks, the dose-limiting toxicity (DLT) was elevation of 
liver enzymes, which was also the most common toxicity, 
with grade 3 and 4 events observed in 41 and 14% of cycles 
respectively. Grade 3–4 haematological toxicity was rare, 
occurring in only 2 patients. Fatigue was another frequently 
encountered side effect and was judged at least moderate-
to-severe in 24% of patients. Renal toxicity was observed in 
4 patients, with 1 patient experiencing grade 3 and another 
experiencing grade 4 toxicity. No objective responses were 
seen in this trial.
In the French study trabectedin was administered as a 
24 hours continuous infusion every 3 weeks (Taamma et al 
2001). This trial enrolled 52 patients with various types of 
malignancies including 12 patients with sarcomas. Twenty 
seven patients were treated in an escalating dose phase 
and 25 more patients were treated in an extended phase at 
the recommended dose. The MDT was 1800 µg/m² every 
3 weeks, and the recommended dose was 1500 µg/m². The 
DLT in this study was haematological (grade 4 neutropenia 
and thrombocytopenia), and was also the most common 
toxicity, grade 3–4 neutropenia and thrombocytopenia were 
seen in 52% and 28% of patients and 38% and 10% of cycles 
respectively at the recommended dose. Transient elevation 
of liver enzymes (AST/ALT) was the most common non-
haematological toxicity, grade 3–4 events were observed in 
38% of patients. Asthenia was also a common side effect 
of treatment, but was severe (ie, grade 3–4) in only 8% of 
patients. Partial response occurred in 3 patients: one with 
breast cancer, one with osteosarcoma and one with STS.
In a third phase I trial conducted by the EORTC, the 
planned schedule for administration of trabectedin was 
a 1 hour infusion every 3 weeks, however the MDT was 
1100 µg/m² with this schedule and the study was extended Therapeutics and Clinical Risk Management 2008:4(1) 111
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by protocol amendment, allowing patients to be treated 
with a 3-hour schedule at higher doses of trabectedin, up to 
1800 µg/m² (Twelves et al 2003). Seventy-two patients were 
included in this study. The DLT were grade 4 neutropenia 
and thrombocytopenia and grade 3 fatigue using the 1-hour 
infusion and grade 4 thrombocytopenia, grade 3 fatigue and 
grade 3 bilirubinemia using the 3-hour infusion. The most 
common toxic side effects were haematological, with grade 
3–4 neutropenia and thrombocytopenia in 20% and 10% 
respectively. The most common non-haematological side 
effects were nausea and vomiting, fatigue and biochemi-
cal hepatic toxicity. Two objective tumor responses were 
observed, both in the 3-hour infusion cohort. Both of the 
responding patients had sarcoma (uterine leiomyosarcoma 
and stromal colon sarcoma).
Another phase I trial was reported a year later, using 
a daily bolus × 5 days repeated every 3 weeks (Villalona-
Calero et al 2002). Neutropenia and thrombocytopenia were 
the DLT and transient elevation of transaminases was also 
frequently observed. The maximum tolerated dose in this 
trial was 325 µg/m²/day × 5 every 3 weeks which is not 
signiﬁ  cantly different from the recommended 1500 µg/m²/
cycle dose derived from other trials, indicating that toler-
ance of trabectedin was not enhanced by this schedule. Of 
note, antitumor activity was observed in a patient with STS 
(leiomyosarcoma).
Nausea and vomiting was a frequently encountered 
side effect in all trials, but was easily managed with 5HT3-
antagonists. The difference in the DLT and the MDT in the 
trial by Ryan et al and the other phase I trials reported by 
Taamma et al (2001) and Twelves et al (2003) was due to 
a slight difference in the deﬁ  nition of the DLT. Indeed in 
the American trial grade 3–4 transminitis was considered a 
DLT if recovery was not complete by day 21, while the 2 
other trials allowed 28 days for complete recovery of grade 
3–4 toxicity.
Based on the results of these different phase I trials the 
recommended dose and schedule for phase II trials was 
1500 µg/m² as a 24-hour continuous infusion repeated every 
3 weeks (Garcia-Carbonero et al 2004; Yovine et al 2004; Le 
Cesne et al 2005). The most commonly observed toxicities 
in phase II trials were neutropenia, thrombocytopenia and 
elevation of liver enzymes (Table 1).
Prevention of severe toxicity
Pharmacokinetic studies conducted during the phase I trials 
have allowed the identiﬁ  cation of several factors predictive 
of severe toxicity during treatment with trabectedin (Gomez 
et al 2000; Taamma et al 2001). Most notably abnormal 
serum alkaline phosphatase level at baseline was a predictor 
of liver enzymes elevation (Taamma et al 2001) and baseline 
serum bilirubin above 0.6 × ULN was a predictor of severe 
toxicity (haematological and hepatic).
Grosso, Dileo et al (2006) recently reported the use of 
steroid premedication to prevent biochemical hepatic and 
haematological toxicity. In this retrospective study, 54 
patients with STS, osteosarcoma or Ewing tumors received 
trabectedin in a compassionate-use program between April 
2000 and 2005. Based on the observation that pre-treatment 
with dexamethasone signiﬁ  cantly reduced hepatotoxicity 
of trabectedin in rats (Donald et al 2003), patients treated 
after April 2002 received dexamethasone 4 mg twice daily 
beginning the day before administration of trabectedin. 
Twenty-three patients were treated without dexametha-
sone premedication and 31 received dexamethasone prior 
to trabectedin. In the group receiving dexamethasone the 
Table 1 Main toxicities observed in phase II trials in patients with soft tissue sarcoma
Reference  Study type  N  Grade 3–4  Febrile  Grade 3–4   Grade 3–4
     neutropenia  neutropenia  thrombocytopenia  transaminitis
Delaloge et al 2001  Phase I + compassionate-  29  48.4%  10.3%  20.6%  52.0%
 use  program
Yovine et al 2004  Phase II, second line  54  61%  7%  19%  48% ALT
           57%  ALT
Garcia-Carbonero  Phase II, second line  36  34%  6%  17%  26% AST
et al 2004            20%ALT
Le Cesne et al 2005  Phase II, second line  104  52.5%  9.1%  18.2%  35.3% AST
           44.5%  ALT
Garcia-Carbonero Phase  II,  ﬁ  rst line  36  33%  0%  0%  34% AST
et al 2005            36% ALT
Huygh et al 2006  Phase II + compassionate-  89  35.9%  7.9%  17.9%  34.9%
 use  programTherapeutics and Clinical Risk Management 2008:4(1) 112
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incidence of grade 3–4 liver enzyme elevation, neutropenia 
and thrombocytopenia fell to 3%, 10%, and 0% respectively, 
compared with 70%, 39%, and 35% respectively in the group 
without premedication (p   0.0001 using the χ² for elevated 
liver enzymes and neutropenia, no p-value reported for the 
difference in the rate of thrombocytopenia). The progres-
sion free survival (PFS) was comparable in both groups (no 
numerical nor p-values reported) and the PFS for the whole 
cohort was in the range of that reported in phase II trials. 
Since these data are derived from a retrospective study they 
need to be validated in a prospective trial before steroid 
premedication can be safely used in clinical practice. Indeed, 
although steroid premedication seems to lower trabectedin 
toxicity, the mechanism by which it does so in humans is still 
unknown, and one may wonder whether or not dexametha-
sone inﬂ  uences the pharmacokinetics of trabectedin. In the rat 
model described by Donald and colleagues dexamethasone 
premedication lowered the levels of trabectedin in the liver 
(both maximal concentration and area under the curve) with-
out lowering the plasma level (Donald et al 2003), however 
these data need to be conﬁ  rmed in humans.
Efﬁ  cacy of trabectedin in sarcoma
Trabectedin in non-gastrointestinal 
stromal tumors (non-GIST) STS
The ﬁ  rst paper to speciﬁ  cally report clinical activity of 
trabectedin in STS was published in 2001 by Delaloge et al 
(2001). This study included 12 patients with STS entered in 
the phase I reported by Taamma et al (2001) and 17 patients 
with STS entered in a compassionate-use program. Overall 
the author observed 4 partial responses (PR) (14%), 10 
disease stabilisation (SD) (34%) lasting more than 2 months. 
The median time to progression was 2.8 months. Eight 
patients (28%) were progression free at 6 months and 4 
(14%) were progression-free at 12 months. These results were 
quite impressive considering that all patients had received 
both doxorubicin and an alkylating agent prior to treatment 
with trabectedin.
Yovine et al (2004) reported the results a French phase 
II trial of trabectedin 1500 µg/m² administered as a 24-hour 
continuous infusion in patients with progressive STS after 
at least one prior chemotherapy regimen. Fifty-four patients 
were accrued between February 1999 and January 2001 
into 2 different cohort based on prior treatment: group 1, 1 
or 2 drugs (n = 26); group 2, 3 or more drugs (n = 28). All 
patients in this trial had a good ECOG performance status 
(PS) (0 or 1). Leiomyosarcoma was the predominant his-
tological subtype (n = 22, 41%, with uterine origin in 8 of 
22 cases) followed by liposarcoma (11%), 4 patients (7%) 
had GIST. All patients had metastatic disease at the time of 
study entry. Two patients had PR (3.7%), 9 patients (17%) 
had SD for more than 6 months and 28 patients (51.9%) had 
progressive disease. After a median follow-up of 26 months, 
the median PFS was 1.9 months, and 38.8% and 24.1% of 
patients were progression-free at 3 and 6 months respectively. 
Of note the PFS and the 3 and 6 months progression-free rate 
were similar between the two groups. Median overall survival 
was 12.8 months, and was longer in group 1 than in group 2 
(14 versus 8 months respectively) (Yovine et al 2004).
Garcia-Carbonero et al reported the results of the 
American phase II trial of trabectedin 1500 µg/m² admin-
istered as a 24-hour continuous infusion in 36 patients with 
progressive STS after failure of at least one prior chemo-
therapy regimen (Garcia-Carbonero et al 2004). This study 
enrolled 36 patients between September 1999 and September 
2000. All patients had metastatic disease, good ECOG PS 
(0–1) and most of them had either leiomyosarcoma (n = 13, 
36%) or liposarcoma (n = 10, 28%). All patients were also 
previously treated with anthracycline containing regimens. 
One complete response (CR), 2 PR (objective response 
rate, CR + PR = 8%) were observed. Median PFS was 
1.7 months and the 6 and 12 months progression-free rate 
were approximately 20% and 10%. Median overall survival 
was 12.1 months
A third study of trabectedin 1500 µg/m² as a 24-hour 
continuous infusion was conducted by the EORTC and 
reported by Le Cesne et al (2005). This trial accrued 
104 patients with non-GIST STS failing prior chemo-
therapy, as well as 28 patients with progressive GIST (Blay 
et al 2004; Le Cesne et al 2005). The results of trabectedin 
in patients with GIST were reported separately and will 
be discussed in the next paragraph. All patients treated 
in the STS cohort had good PS (0–1), the most common 
histological subtypes were leiomyosarcoma (41%), syno-
vial sarcoma (17%) and liposarcoma (10%). There were 8 
(7.7%) PR and 45 (43.3%) SD. After a median follow-up 
of 34 months, the median PFS was 3.4 months (105 days) 
and the median overall survival was 9.2 months. Fifty-two 
percent, 29% and 17% of patients were progression-free at 
3, 6 and 12 months respectively.
A single institution’s experience was reported by investi-
gators from the Leuven Cancer Institute in Leuven, Belgium 
(Huygh et al 2006). This report addresses the outcome of 89 
patients, 15 of whom were treated in a phase II trial, while 
74 other patients were treated on a compassionate-use pro-
gram. Most patients had leiomyosarcoma (33%), liposarcoma Therapeutics and Clinical Risk Management 2008:4(1) 113
Trabectedin in soft tissue sarcoma
(18%) or osteosarcoma (16%), and all but 3 had received 
prior chemotherapy, in most cases with doxorubicin (93%). 
The objective response rate in this heterogeneous cohort 
was 7% (1 CR and 5 PR), and 32 disease stabilization (36%) 
were also observed. Median PFS and overall survival were 
2.0 and 8.2 months respectively. Toxicity in this unselected 
population was similar to that observed in phase II trials 
(Table 1).
Based on the interesting results seen in patients failing 
prior chemotherapy, a phase II trial in chemotherapy-naive 
patients with advanced STS was launched in September 
1999 (Garcia-Carbonero et al 2005). This study accrued 
36 patients with good ECOG PS (0–1), most of whom had 
either leiomyosarcoma (42%) or liposarcoma (25%). Six 
patients had PR (17%) for a median duration of 16.5 (range 
5.1–32.5) months. Overall the median PFS was 1.6 months 
and the median overall survival was 15.8 months, however 
the 6- and 12-months PFS rates were 24.4 and 21% indicating 
that approximately 20% of patients achieve long-term tumor 
control. The main efﬁ  cacy outcomes of trabectedin in these 
phase II trials are reported in Table 2.
A randomized phase II trial comparing trabectedin 
given at 580 µg/m² on a weekly schedule to the “standard” 
1500 µg/m² 24-hour continuous infusion every 3 weeks 
schedule in patients with leiomyosarcoma or liposarcoma 
failing prior therapy with doxorubicin and ifosfamide was 
ﬁ  rst reported at the 2004 ASCO meeting (Samuels et al 2004) 
was updated at the 2007 ASCO meeting (Morgan et al 2007). 
Two hundred and seventy patients were accrued, all had 
received at least one prior chemotherapy regimen (median 
2, range 1–6). Progression-free survival was statistically 
superior in the standard, 1500 µg/m² 24-hour continuous 
infusion every 3 weeks, arm (3.3 vs 2.3 months, p = 0.0418), 
while OS was not statistically different between arms (13.8 
vs 11.8 months, p = 0.1984). More neutropenia, increase in 
liver enzymes, emesis and fatigue occurred in the standard 
dosing arm (Morgan et al 2007).
Trabectedin in patients with GIST
Two trials have investigated the efﬁ  cacy of trabectedin in 
GISTs. In both of these trials trabectedin was found to be 
inefﬁ  cient in this disease. The ﬁ  rst trial was reported by Ryan 
et al (2002) and included 20 patients, most of whom were 
chemotherapy-naïve (55%). Trabectedin was administered as 
a 24-hour continuous infusion of 1500 µg/m² every 3 weeks. 
The best response in this study was stable disease, which was 
observed in 2 patients (10%), lasting 4 and 10 cycles (12 and 
30 weeks). The median PFS was 1.25 months, and the overall 
survival was not reached after more than 15 months of median 
follow-up. However this extended overall survival was due 
to the fact that most patients received imatinib (GLIVEC®/
GLEEVEC®, Novartis, Basel, Switzerland) after failure of 
trabectedin. The median survival of the 7 patients who did 
not receive imatinib was 8.6 months (Ryan et al 2002).
Another trial, led by the EORTC and reported by Blay 
et al (2004), enrolled 28 patients, trabectedin was given as a 
24-hour continuous infusion of 1500 µg/m² every 3 weeks. 
Patients were required by protocol to be chemotherapy-naïve. 
No objective responses were seen but 9 patients (33%) had 
stable disease at the ﬁ  rst response assessment (2 cycles). 
The median PFS was 51 days (1.7 months) and the median 
overall survival was 589 days (19.3 months), here again 
reﬂ  ecting the fact that the 18 patients who received “further 
medical treatment after trabectedin” likely received imatinib 
(Blay et al 2004).
Factors predicting response 
to trabectedin
All phase II trials have shown that trabectedin, despite a 
relatively low response rate, could induce long term tumor 
Table 2 Main efﬁ  cacy outcomes of trabectedin in phase II trials in patients with non-GIST soft tissue sarcoma
Reference  Study type  N  Response  Median PFS  6-month  Median OS
     rate  (months)  PFS  (months)
Delaloge et al 2001  phase I + compassionate-  29  14.0%  2.8  28.0%  NR
 use  program
Yovine et al 2004  Phase II, second line  54  3.7%  1.9  24.1%  12.8
Garcia-Carbonero  Phase II, second line  36  8.0%  1.7  20.0%  12.1
et al 2004
Le Cesne et al 2005  Phase II, second line  104  8.0%  3.4  29.0%  9.2
Garcia-Carbonero Phase  II,  ﬁ  rst line  36  17.1%  1.6  24.4  15.8
et al 2005
Huygh et al 2006  Phase II + compassionate-  89  7.0%  2.0  NR  8.2
 use  program
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control in approximately 15–20% of patients, several 
retrospective studies have focused on the identiﬁ  cation of 
these patients.
Grosso et al (Grosso, Demetri et al 2006a; Grosso, Jones 
et al 2007) reported on the activity of trabectedin in myxoid 
liposarcoma. Myxoid liposarcoma contains a characteristic 
chromosomal translocation, t(12; 16), resulting in the fusion 
of a transcription factors (CHOP) and an RNA binding 
protein (TLS/FUS) (Crozat et al 1993). At least 3 different 
fusion products have been identiﬁ  ed, based on the TLS/FUS 
breakpoint, but were not shown to have prognostic signiﬁ  -
cance (Antonescu et al 2001). In the retrospective analysis 
performed by Grosso, Forni et al (2007), 51 patients with 
myxoid liposarcoma were treated in 5 different European 
and American institutions. The overall response rate using 
RECIST criteria was 51% (CR = 4%, PR = 47%), with 
SD seen in 39% patients. The 6 months PFS rate was 88% 
and the median PFS was 14 months (Grosso, Jones et al 
2007). Preliminary data based on the observation made on 
12 patients for whom fresh frozen tissue was available for 
RT-PCR experiments showed that probability of response 
was inﬂ  uenced by the type of fusion transcript present in the 
tumor: 2 patients with type III fusion transcript had disease 
progression as their best response (PFS 1.3 months in both 
patients), while the remaining 10 patients who had type I, II 
and/or IV fusion transcript had at least a PR following treat-
ment with trabectedin (PFS ranging from 6.7 to 20.5 months) 
(Grosso, Jones et al 2007). In an in vitro study using primary 
cell culture, Grosso et al also reported that in the myxoid lipo-
sarcoma cell line carrying the type I transcript, impairment of 
the selective binding of FUS-CHOP to some promoters was 
observed after treatment with trabectedin at concentration 
1–4 nM (Grosso, Forni et al 2007).
Based on the observation that functional status of both 
NER and HRR inﬂ  uences the activity of trabectedin in pre-
clinical models (Herrero et al 2006), Schöffski et al (2006) 
conducted a retrospective analysis of the NER and HRR 
status, using RT-PCR, on the tumors of 92 patients treated 
with trabectedin. In this study patients with higher ERCC1 
expression (part of the NER machinery) had improved 
6-month PFS rate and median overall survival compared with 
patients whose tumor expressed lower levels of ERCC1 (32 
versus 15%, p = 0.07 and 12 versus 7 months respectively). 
Furthermore patients whose tumor expressed lower levels 
of BRCA1 (part of the HRR system) also had improved 
6-month PFS rate and median overall survival compared 
with patients whose tumor expressed high levels of BRCA1 
(33 vs 11%, p = 0.02 and 15 vs 5 months, p = 0.0003, for 
PFS and OS respectively). BRCA2 (HRR system) and 
XPD (NER system) expressions had no signiﬁ  cant impact 
on PFS and survival. A combined analysis of ERCC1 and 
BRCA1 expression identiﬁ  ed a subgroup of patients with 
high ERCC1 and low BRCA1 expression who had a 50% 
6-month PFS rate (p = 0.0003) and a 20.4 months median 
overall survival (p = 0.0005). Multivariate analysis showed 
that both ERCC1 (hazard ratio for progression for high level 
= 0.52, p = 0.02) and BRCA1 (hazard ratio for progression for 
high expression level = 2.73, p = 0.0006) expression levels 
were independent predictors of PFS and that only BRCA1 
independently predicted overall survival (hazard ratio for 
death for high level = 2.57, p = 0.0005).
Perspective and future 
developments
Several trabectedin-based combinations have been tested in 
phase I trials, including combination with cisplatin (Grasselli 
et al 2007) capecitabine (Gore et al 2006), paclitaxel (Papa-
dopoulos et al 2006), docetaxel (Von Mehren et al 2006) 
and pegylated doxorubicin (Cohen et al 2005). These tri-
als have shown that combination therapy with trabectedin 
was feasible and induced responses or prolonged disease 
stabilizations in tumor types known to be sensitive either to 
trabectedin or to the drug it was combined to. Neither major 
drug-drug interactions nor major unpredicted toxicity were 
observed in these trials. Several of these combination are 
based on the observation of synergy in preclinical models: 
cisplatin-trabectedin combination for example was shown to 
be synergistic in various human tumor xenografts (D’Incalci 
et al 2003) and treatment of sarcoma or breast cancer cells 
with doxorubicin or paclitaxel 24 hours prior to treatment 
with trabectedin was shown to be synergistic, both in vitro 
and in vivo in nude mice (Takahashi et al 2001, 2002).
Another direction of ongoing research is the identiﬁ  cation 
of patients with a high probability of beneﬁ  t from treatment 
with trabectedin. Preliminary data reported at the 2006 and 
2007 ASCO meetings regarding predictive factors in patients 
undergoing treatment with trabectedin (Grosso, Demetri et al 
2006; Schoffski et al 2006; Grosso, Forni et al 2007; Grosso, 
Jones et al 2007) will need validation in larger cohorts and 
possibly in prospective trials before treatment can be allo-
cated based on these factors.
Conclusion
Trabectedin binds the DNA minor groove and has an original 
mechanism of action involving proteins of the nucleotide 
excision repair machinery. Trabectedin has shown promising Therapeutics and Clinical Risk Management 2008:4(1) 115
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activity in patients with STS, with long-term (12 months) 
disease control achieved in approximately 20% of patients in 
ﬁ  rst line advanced disease and approximately 15% in second 
line chemotherapy. In patients with normal hepatic function 
assessed by normal bilirubin and alkaline phosphatases (ALP), 
trabectedin can be safely administered at 1500 µg/m² every 
3 weeks, the dose should however be lowered to 1200 µg/m² 
in case of a rise in bilirubin or ALP between cycles (Le Cesne 
et al 2005). Development in patients with other malignancies 
such as breast and ovarian carcinoma is currently ongoing. 
Further development in STS should be based on biological 
and/or histological factors predictive of response.
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